Pharmacovigilance Regulations and Application: Safeguarding Drug Safety in a Complex Global Environment

Introduction to Pharmacovigilance

Pharmacovigilance (PV) is the science and practice of identifying, analyzing, comprehending, and preventing side effects or other drug-related issues (Bate, 2019).  In a pharmaceutical world characterized by rapid innovation and international marketplaces, safeguarding medication safety beyond commercialization has never been more important. Regulatory agencies throughout the world have built tough PV frameworks to guarantee that once a product has been authorized, it is rigorously monitored (Biomapas, n.d.). Effective pharmacovigilance is critical not just for meeting regulatory obligations, but also for protecting patients and maintaining trust in healthcare systems.

Regulatory Landscape

Global Harmonization Efforts

Modern pharmacovigilance rules are based on the International Council for Harmonisation (ICH) recommendations, namely ICH E2E (Pharmacovigilance Planning) and ICH E2D (Post-Approval Safety Data Management) (CDER, 2018) (CDER, 2024c).  These frameworks help businesses build risk management strategies and report unfavorable occurrences efficiently.  Regulatory bodies such as the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) have accepted ICH principles, although regional disparities remain.

For example, the EMA requires the use of EudraVigilance for electronic reporting of suspected adverse events, but the FDA requires submission via the FDA Adverse Event Reporting System (FAERS) database (EMA, 2013) (CDER, 2024a). In low- and middle-income nations, WHO's Programme for International Drug Monitoring and its worldwide database VigiBase, which is administered by the Uppsala Monitoring Centre, are crucial (UMC, n.d.).

South Korea’s Ministry of Food and Drug Safety (MFDS) is responsible for PV, but has not explicitly accepted ICH recommendations. Likewise, it is not entirely clear whether China’s National Medical Products Administration (NMPA) and the Center for Drug Evaluation (CDE) strictly follow the IHC in their PV efforts.

Risk Management Plans (RMPs) and REMS

Regulators may demand Risk Management Plans (EU) or Risk Evaluation and Mitigation Strategies (REMS in the US) as part of the medication approval process (EMA, 2006) (CDER, 2023). These frameworks proactively evaluate safety signals and require risk-reduction measures such as regulated distribution programs, instructional materials for healthcare professionals, and post-marketing clinical trials.

Application of Pharmacovigilance in Practice

Spontaneous Reporting and Signal Detection

Spontaneous reporting is a key component of PV. Healthcare personnel and patients report suspected adverse drug reactions (ADRs), which are subsequently entered into safety databases. With hundreds of complaints filed worldwide, signal identification algorithms, ranging from disproportionality analysis to Bayesian methods, are utilized to identify possible safety problems that require additional examination (Liu, 2024).

However, spontaneous reports are frequently characterized by underreporting, duplication, and a lack of causation information. As a result, more complex techniques using real-world data are being introduced to supplement existing systems.

Real-World Evidence (RWE)

To counter the limits of spontaneous reporting, authorities are increasingly relying on real-world information gathered from electronic health records, insurance claims, patient registries, and social media data.  This larger viewpoint aids in the identification of long-term or unusual side effects that were not observed in clinical studies.  The FDA's Sentinel Initiative and the EU's DARWIN EU network are important projects that provide proactive safety monitoring with real-world data (CDER, 2024b) (EMA, 2025).

Periodic Safety Update Reports (PSURs) and Development Safety Update Reports (DSURs)

Marketing Authorization Holders (MAHs) are required to submit Periodic Safety Update Reports (PSURs) or Periodic Benefit-Risk Evaluation Reports (PBRERs) at certain intervals following approval (ProPharma, 2024). These reports include safety data from a variety of sources to determine the benefit-risk profile.  Similarly, throughout the clinical process, Development Safety Update Reports (DSURs) provide yearly safety updates for experimental drugs (CDER, 2020).

Technological Integration in Pharmacovigilance

Automation and AI in Safety Monitoring

The massive amount of safety data has made automation and artificial intelligence (AI) indispensable technologies in contemporary PV. Machine learning models can assist in identifying bad event trends, classifying severity, and prioritizing signal examination.  Natural Language Processing (NLP) is used to search social media and scholarly publications for new safety signals (Aronson, 2022).

GenAI for Narrative Writing and Case Processing

Generative AI is emerging as a transformational asset for creating case narratives and analyzing signals. GenAI can summarize patient reports, create MedWatch filings, and aid safety professionals by automating low-risk chores, freeing them up to focus on high-complexity signals.  These innovations are improving pharmacovigilance processes and lowering human error (Mishra, 2025).

Pharmacovigilance in Special Populations

Pediatric and Geriatric Monitoring

Children and older people frequently react differently to drugs due their specific metabolic and physiological state. Regulatory authorities require these groups to undergo particular risk evaluations and post-marketing surveillance. Enhanced surveillance of these people is critical for detecting adverse drug reactions (ADRs) that may not be present in regular adult populations (Biomapas, n.d.a) (EMA, n.d.).

Pregnancy Registries

Pregnancy outcomes are seldom examined in clinical trials, thus post-marketing pregnancy exposure registries monitor mother and fetal health in real-world settings.  This information influences label modifications and risk communication efforts for medications taken during pregnancy (Mahadevan, 2024).

Pharmacovigilance and Public Health

Vaccine Safety Monitoring

The COVID-19 epidemic highlighted the significance of strong PV systems. Global authorities significantly increased vaccination adverse event reporting and real-time safety reviews. Post-vaccine myocarditis complaints and thrombosis signals were quickly discovered and handled because of excellent PV methods including spontaneous reporting systems, data mining, and signal detection.

For example, an observational self-controlled case series from a database (data mining) revealed a higher incidence of myocarditis 1-7 days after the first dose of ChAdOx1, BNT162b2, and mRNA-1273 vaccinations, as well as after the second dose of BNT162b2 and mRNA-1273 (Patone, 2021).  Furthermore, there was a higher risk of hospitalization or mortality for pericarditis 1-7 days and 8-14 days following a SARS-CoV-2 positive test. In contrast, the initial dosage of ChAdOx1 and BNT162b2 was linked with a lower incidence of cardiac arrhythmia. However, SARS-CoV-2 infection (COVID-19 disease) also increased the incidence of myocarditis, pericarditis, and cardiac arrhythmia and is associated with a much higher risk of severe outcomes such as hospitalization, long-term health effects, and death, indicating a risk-benefit in favour of vaccination (Patone, 2021).

Communication and Transparency

Modern pharmacovigilance relies heavily on transparent risk communication. Public safety warnings, label revisions, and press releases help keep healthcare practitioners and patients informed. Collaborative tools such as Medical Dictionary for Regulatory Activities (MedDRA) maintain uniform terminology, allowing for improved communication across jurisdictions (ICH, n.d.).

Challenges and the Road Ahead

Despite advancements, several challenges remain:

● Data silos: Fragmented data sources mask danger signals.

● Resource Burden: Meeting PV regulations can be costly, particularly for small and medium-sized businesses that aim to be marketing authorization holder, one reason why many look for acquisition by big pharma (Kozak, 2025).

● Global disparities: Developing countries frequently lack the infrastructure for rigorous PV monitoring (Elshafie, 2018).

Future advancements in global harmonization, automation, and cross-sector data exchange are required to remove these barriers.  Collaborations between regulators, pharmaceutical companies, and technology businesses will be important in designing the next generation of pharmacovigilance.

Conclusion

Pharmacovigilance is not merely a regulatory obligation—it is a public health imperative. As the pharmaceutical industry evolves toward more personalized therapies, biologics, and rapid product development, the role of pharmacovigilance will only grow in significance. Through a combination of rigorous regulatory frameworks, real-world data integration, and emerging AI tools, pharmacovigilance systems are becoming more proactive and patient-centered. By anticipating and mitigating drug-related risks, pharmacovigilance ensures that innovation in medicine does not come at the expense of safety. Ultimately, a robust pharmacovigilance ecosystem supports better patient outcomes, trust in health systems, and sustainable pharmaceutical innovation.

Sources:

Aronson, J. K. (2022). Artificial Intelligence in Pharmacovigilance: An Introduction to Terms, Concepts, Applications, and Limitations. Drug Safety, 45(5), 407–418. https://doi.org/10.1007/s40264-022-01156-5

Bate, A., Hornbuckle, K., Juhaeri, J., Motsko, S. P., & Reynolds, R. F. (2019). Hypothesis-free signal detection in healthcare databases: Finding its value for pharmacovigilance. Therapeutic Advances in Drug Safety, 10, 2042098619864744. https://doi.org/10.1177/2042098619864744

Biomapas. (n.d.a). EMA & FDA: What are the similarities & differences in risk management procedures?. biomapas.com. https://www.biomapas.com/ema-and-fda-risk-management/

Biomapas. (n.d.). Setting up a pharmacovigilance system. biomapas.com. https://www.biomapas.com/setting-up-a-pharmacovigilance-system/

CDER. (2018, August 24). E2E pharmacovigilance planning. fda.gov. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2e-pharmacovigilance-planning

CDER. (2020, April 9). E2F development safety update report. fda.gov. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2f-development-safety-update-report

CDER. (2024a, November 8). FDA’s adverse event reporting system (FAERS). fda.gov. https://www.fda.gov/drugs/surveillance/fdas-adverse-event-reporting-system-faers

CDER. (2024b, March 8). FDA’s Sentinel initiative. fda.gov. https://www.fda.gov/safety/fdas-sentinel-initiative

CDER. (2024c, March 14). Guidance document: E2D(R1) Post-Approval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports. fda.gov. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2dr1-post-approval-safety-data-definitions-and-standards-management-and-reporting-individual-case

CDER. (2023, May 16). Risk evaluation and mitigation strategies (REMS). fda.gov. https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems

Elshafie, S., Zaghloul, I., & Roberti, A. M. (2018). Pharmacovigilance in developing countries (part I): Importance and challenges. International Journal of Clinical Pharmacy, 40(4), 758–763. https://doi.org/10.1007/s11096-017-0570-z

EMA. (2025, April 22). Darwin EU. darwin-eu.org. https://www.darwin-eu.org/

EMA. (2013, June 19). Eudravigilance. ema.europa.eu. https://www.ema.europa.eu/en/human-regulatory-overview/research-development/pharmacovigilance-research-development/eudravigilance

EMA. (n.d.). Good pharmacovigilance practices (GVP). ema.europa.eu. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/good-pharmacovigilance-practices-gvp

EMA. (2006, September 27). Risk management plans. ema.europa.eu. https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/pharmacovigilance-marketing-authorisation/risk-management/risk-management-plans

ICH. (n.d.). Welcome to MedDRA. meddra.org. https://www.meddra.org/

Kozak, J. (2025, February 7). M&A in pharma: Balancing growth and risk. pharmaceuticalcommerce.com. https://www.pharmaceuticalcommerce.com/view/m-a-in-pharma-balancing-growth-and-risk

Liu, L. (2024). A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1397029

Mahadevan, U., Levy, G., Gensler, L., Ali, M., Lacerda, A. P., Wegrzyn, L., Palac, H., Bhutani-Jacques, T., Long, M., Clowse, M. E. B., Kimball, A. B., Chambers, C., & Scialli, A. R. (2024). Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and Postmarketing Reports. Drug Safety, 47(10), 1039–1049. https://doi.org/10.1007/s40264-024-01454-0

Mishra, H. P., & Gupta, R. (2025). Leveraging Generative AI for Drug Safety and Pharmacovigilance. Current Reviews in Clinical and Experimental Pharmacology, 20(2). https://doi.org/10.2174/0127724328311400240823062829

Patone, M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar-Hari, M., Watkinson, P., Khunti, K., Harnden, A., Coupland, C. A. C., Channon, K. M., Mills, N. L., Sheikh, A., & Hippisley-Cox, J. (2022). Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nature Medicine, 28(2), 410–422. https://doi.org/10.1038/s41591-021-01630-0

ProPharma. (2024, May 23). Understanding the PSUR and PBRER. propharmagroup.com. https://www.propharmagroup.com/thought-leadership/understanding-the-psur-and-pbrer

UMC. (n.d.). About Vigibase. who-umc.org. https://who-umc.org/vigibase/